Serenoa repens: The Scientific Basis for the Treatment of Benign Prostatic Hyperplasia

Buck, 2004, Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action, J Urol, 172, 1792, 10.1097/01.ju.0000140503.11467.8e Gerber, 2004, The role of a lipido-sterolic extract of Serenoa repens in the management of lower urinary tract symptoms associated with benign prostatic hyperplasia, BJU Int, 94, 338, 10.1111/j.1464-410X.2004.04962.x Habib, 2004, Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract, Prostate Cancer Prostatic Dis, 7, 195, 10.1038/sj.pcan.4500746 Paubert-Braquet, 1998, Effect of the lipidosterolic extract of Serenoa repens (Permixon®) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies, Eur Urol, 33, 340, 10.1159/000019570 Bayne, 1999, Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor—new evidence in a coculture model of BPH, Prostate, 40, 232, 10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0 Chevalier, 1997, Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (Permixon) supplemented with [1-14C]-lauric acid, [1-14C]-oleic acid or [4-14C]-beta-sitosterol, Eur J Drug Metab Pharmacokinet, 22, 73, 10.1007/BF03189787 Habib FK, Ross M, Bayne CW, et al. The localisation and expression of 5α-reductase types I and II mRNAs in human hyperplastic prostate and in prostate primary cultures. J Endocrinol 1998;156:509–17. Iehle, 1999, Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue, J Steroid Biochem Mol Biol, 68, 189, 10.1016/S0960-0760(99)00030-8 Di Silverio, 1998, Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia, Prostate, 37, 77, 10.1002/(SICI)1097-0045(19981001)37:2<77::AID-PROS3>3.0.CO;2-I Habib, 2005, Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression, Int J Cancer, 114, 190, 10.1002/ijc.20701 Ravenna, 1996, Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines, Prostate, 29, 219, 10.1002/(SICI)1097-0045(199610)29:4<219::AID-PROS3>3.0.CO;2-6 Vela Navarrete, 2003, BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double-blind pilot clinical assay, Eur Urol, 44, 549, 10.1016/S0302-2838(03)00368-3 Bayne, 2000, The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate, J Urol, 164, 876, 10.1016/S0022-5347(05)67330-2 Vacherot, 2000, Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia), Prostate, 45, 259, 10.1002/1097-0045(20001101)45:3<259::AID-PROS9>3.0.CO;2-G Vela-Navarrete, 2005, Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia, J Urol, 173, 507, 10.1097/01.ju.0000150533.94952.25 Roehrborn, 2010, The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study, Eur Urol, 57, 123, 10.1016/j.eururo.2009.09.035 Agbabiaka, 2009, Serenoa repens (saw palmetto): a systematic review of adverse events, Drug Safety, 32, 637, 10.2165/00002018-200932080-00003 Schmidt, 2004, Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride, J Androl, 25, 944, 10.1002/j.1939-4640.2004.tb03166.x Thomas, 2005, Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer, Prostate, 63, 231, 10.1002/pros.20188 Dreikorn, 2001, Other medical therapies, 481 Wang, 1997, Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells, Cancer Res, 57, 714 Zhu, 2003, Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells, J Androl, 24, 681, 10.1002/j.1939-4640.2003.tb02727.x Sargent, 1991, Partial purification of human prostatic 5alpha-reductase (3-oxo-5alpha-steroid:NADP+ 4-ene-oxido-reductase; EC 1.3.1.22) in a stable and active form, J Steroid Biochem Mol Biol, 38, 73, 10.1016/0960-0760(91)90403-R Savory, 1995, 5alpha-reductase type 1 is localized to the outer nuclear membrane, Mol Cell Endocrinol, 110, 137, 10.1016/0303-7207(95)03526-D Sultan, 1984, Inhibition of androgen metabolism and binding by a liposterolic extract of “Serenoa repens B” in human foreskin fibroblasts, J Steroid Biochem, 20, 515, 10.1016/0022-4731(84)90264-4 Castro, 2004, Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia, Prostate, 60, 153, 10.1002/pros.20051 Di Silverio, 2003, Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis, Eur Urol, 43, 164, 10.1016/S0302-2838(02)00548-1 Kramer, 2007, Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?, Eur Urol, 51, 1202, 10.1016/j.eururo.2006.12.011 Nickel, 2008, The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial, Eur Urol, 54, 1379, 10.1016/j.eururo.2007.11.026 Steiner, 2003, Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate, Prostate, 56, 171, 10.1002/pros.10238 Kramer, 2002, Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types and effect of differentially expressed cytokines on stromal cell proliferation, Prostate, 52, 43, 10.1002/pros.10084 Wang, 2004, Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2 and cell proliferation in the glandular epithelium, Prostate, 61, 60, 10.1002/pros.20061 Paubert-Braquet, 1997, Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils, Prostaglandins Leukot Essent Fatty Acids, 57, 299, 10.1016/S0952-3278(97)90548-2 Kyprianou, 1996, Apoptotic versus proliferative activities in human benign prostatic hyperplasia, Hum Pathol, 27, 668, 10.1016/S0046-8177(96)90396-2 Scaglione, 2008, Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells, Pharmacology, 82, 270, 10.1159/000161128